The Impact of Obesity and Nutrition on Chronic Liver Diseases, An Issue of Clinics in Liver Disease, 1st Edition
Author :
By Zobair Younossi, MD, MPH
Internationally renowned experts present topics related to obesity, nutrition, and liver disease in this issue. In the first article, the epidemiology of obesity and its association with liver disease are covered. The following two articles focus on
...view more
Internationally renowned experts present topics related to obesity, nutrition, and liver disease in this issue. In the first article, the epidemiology of obesity and its association with liver disease are covered. The following two articles focus on the roles that visceral adipose tissue and microbiota potentially play in the pathogenesis of obesity-related liver disease. The next article focuses on the hepatic pathology seen in patients with obesity-related liver disease and those with malnutrition. The next five articles are focused on NAFLD and provide in-depth data on the natural history and treatment strategies for patients with NAFLD. The next six articles deal with the impact of obesity on other liver diseases and on special populations including children and liver-transplant recipients. The final article provides the most updated information regarding genomics and genetic targets that may provide better prognostic and diagnostic biomarkers and more personalized treatment targets for patients with NAFLD. Cutting-edge information in this issue will help readers gain better understanding of the natural history and pathogenesis of primary and secondary liver diseases associated with obesity. As the information about obesity-related liver disease expands, clinicians will be able to provide more targeted therapeutic options for these patients and develop more accurate diagnostic and prognostic biomarkers.
Internationally renowned experts present topics related to obesity, nutrition, and liver disease in this issue. In the first article, the epidemiology of obesity and its association with liver disease are covered. The following two articles focus on the roles that visceral adipose tissue and microbiota potentially play in the pathogenesis of obesity-related liver disease. The next article focuses on the hepatic pathology seen in patients with obesity-related liver disease and those with malnutrition. The next five articles are focused on NAFLD and provide in-depth data on the natural history and treatment strategies for patients with NAFLD. The next six articles deal with the impact of obesity on other liver diseases and on special populations including children and liver-transplant recipients. The final article provides the most updated information regarding genomics and genetic targets that may provide better prognostic and diagnostic biomarkers and more personalized treatment targets for patients with NAFLD. Cutting-edge information in this issue will help readers gain better understanding of the natural history and pathogenesis of primary and secondary liver diseases associated with obesity. As the information about obesity-related liver disease expands, clinicians will be able to provide more targeted therapeutic options for these patients and develop more accurate diagnostic and prognostic biomarkers.
Author Information
By Zobair Younossi, MD, MPH, Professor and Chairman of the Global NASH/MASH Council (GNC)
eBooks : Built for busy schedules & tailored for your goals.
Affordable knowledge, built for you
Get the resources you need-often at a lower cost than print. Quality content designed to support your goals, without stretching your budget.
Seamless access wherever you are
Open your eBook on your laptop, tablet, or phone - online or offline. Learning fits into your life, no matter where you go.
Always in sync
Start reading on one device and pick up right where you left off on another. Your progress and notes stay with you, every step of the way.
Tools the make learning stick
Highlight key points, take notes, create flashcards, or listen to your eBook read aloud. Interactive features help you deepen your knowledge, your way.
Your eBook is ready whenever you are!
1. Check your email for your access code.
2. Sign into or create your VitalSource account and redeem your code.
The access code for your new eBook will be sent in your order confirmation email. Your code can also be accessed in your My Account section on the Elsevier webshop.
If you do not receive your code within a few minutes, please check your spam folder.
Step-by-step guidance on how to download Bookshelf and also redeem your code can be found here.
The access code for your new eBook does not expire. However, we always suggest redeeming immediately after purchase to start experiencing the benefits of and insights from your purchase. Important to note - the code provided is a single use code and only valid for the edition you purchase. It does not provide access to past nor future editions of the title.
You will have unlimited access to your eBook on the device to which it was downloaded.
Discover the various learning features that our eBooks offer on the Bookshelf® Reader! For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information on the learning functions can be found on the Vitalsource page.
Quality is our top priority. That's why we collaborate with the leading eBook reader provider VitalSource. VitalSource has its own eBook reader Bookshelf®, which you can easily download. This reader is very user-friendly and offers more features than other standard readers. For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information can be found on the Vitalsource page.
Elsevier offers its eBooks in ePub format, as we believe this format is best suited to display our content ideally on as many devices as possible.
You can return your eBook within 13 days of purchase. eBooks that have been partially printed or flipped through more than 15% are excluded from returns.
https://www.elsevierhealth.com.au/the-impact-of-obesity-and-nutrition-on-chronic-liver-diseases-an-issue-of-clinics-in-liver-disease-9780323266642.html294035The Impact of Obesity and Nutrition on Chronic Liver Diseases, An Issue of Clinics in Liver Diseasehttps://secure-ecsd.elsevier.com/covers/80/Tango2/large/9780323266642.jpg131.96175.93AUDInStock/Medicine & Surgery/Gastroenterology & Hepatology/Clinics/Medicine/Gastroenterology & Hepatology/Clinics/Clinics/Medicine/Gastroenterology & Hepatology/Product Format/Clinics/Product Format/Clinics/Product Format/Clinics4335139438872550546075054666525504152598945936812593682659368311418269243350884886536505455351451205259833593680959368235936828Internationally renowned experts present topics related to obesity, nutrition, and liver disease in this issue. In the first article, the epidemiology of obesity and its association with liver disease are covered. The following two articles focus on the roles that visceral adipose tissue and microbiota potentially play in the pathogenesis of obesity-related liver disease. The next article focuses on the hepatic pathology seen in patients with obesity-related liver disease and those with malnutrition. The next five articles are focused on NAFLD and provide in-depth data on the natural history and treatment strategies for patients with NAFLD. The next six articles deal with the impact of obesity on other liver diseases and on special populations including children and liver-transplant recipients. The final article provides the most updated information regarding genomics and genetic targets that may provide better prognostic and diagnostic biomarkers and more personalized treatment targets for patients with NAFLD. Cutting-edge information in this issue will help readers gain better understanding of the natural history and pathogenesis of primary and secondary liver diseases associated with obesity. As the information about obesity-related liver disease expands, clinicians will be able to provide more targeted therapeutic options for these patients and develop more accurate diagnostic and prognostic biomarkers. Internationally renowned experts present topics related to obesity, nutrition, and liver disease in this issue. In the first article, the epidemiology of obesity and its association with liver disease are covered. The following two articles focus on the roles that visceral adipose tissue and microbiota potentially play in the pathogenesis of obesity-related liver disease. The next article focuses on the hepatic pathology seen in patients with obesity-related liver disease and those with malnutrition. The next five articles are focused on NAFLD and provide in-depth data on the natural history and treatment strategies for patients with NAFLD. The next six articles deal with the impact of obesity on other liver diseases and on special populations including children and liver-transplant recipients. The final article provides the most updated information regarding genomics and genetic targets that may provide better prognostic and diagnostic biomarkers and more personalized treatment targets for patients with NAFLD. Cutting-edge information in this issue will help readers gain better understanding of the natural history and pathogenesis of primary and secondary liver diseases associated with obesity. As the information about obesity-related liver disease expands, clinicians will be able to provide more targeted therapeutic options for these patients and develop more accurate diagnostic and prognostic biomarkers.00add-to-cart97803232666422013ProfessionalBy Zobair Younossi, MD, MPH20141Book152w x 229h (6.00" x 9.00")Elsevier02 Dec 2013Please allow 10-14 working days for deliveryBy <STRONG>Zobair Younossi</STRONG>, MD, MPH, Professor and Chairman of the Global NASH/MASH Council (GNC)ClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoNoPlease SelectPlease SelectNoNoPlease Select